Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.

Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE; Club Rhumatismes et Inflammation.

Arthritis Rheum. 2010 Aug;62(8):2458-66. doi: 10.1002/art.27541.

2.

Re-evaluation of biologic therapies in systemic lupus erythematosus.

Bruce IN.

Curr Opin Rheumatol. 2010 May;22(3):273-7. doi: 10.1097/BOR.0b013e3283374e78. Review.

PMID:
20177385
3.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG.

Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233.

4.

Checkpoints in lymphocyte development and autoimmune disease.

von Boehmer H, Melchers F.

Nat Immunol. 2010 Jan;11(1):14-20. doi: 10.1038/ni.1794. Epub 2009 Dec 17. Review.

PMID:
20016505
5.

Therapy: rituximab and PML risk-informed decisions needed!

Calabrese LH, Molloy ES.

Nat Rev Rheumatol. 2009 Oct;5(10):528-9. doi: 10.1038/nrrheum.2009.193. No abstract available.

PMID:
19798025
6.
7.

Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up.

Rückert A, Glimm H, Lübbert M, Grüllich C.

Lupus. 2008 Aug;17(8):757-60. doi: 10.1177/0961203307087876.

PMID:
18625656
9.

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.

Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R.

Ann Rheum Dis. 2008 Dec;67(12):1724-31. doi: 10.1136/ard.2007.083162. Epub 2008 Feb 4.

PMID:
18250115
10.

The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.

Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME.

J Autoimmun. 2008 Feb-Mar;30(1-2):90-8. doi: 10.1016/j.jaut.2007.11.013. Review.

PMID:
18191544
11.

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response.

Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF.

Ann Rheum Dis. 2008 Mar;67(3):330-4. Epub 2007 Sep 7. Erratum in: Ann Rheum Dis.2009 May;68(5):764.

PMID:
17827182
12.

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls.

Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Dörner T.

Ann Rheum Dis. 2008 Apr;67(4):450-7. Epub 2007 Aug 2.

PMID:
17673490
13.

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.

Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y, Takada K, Matsumoto I, Saito K, Koike T.

Mod Rheumatol. 2007;17(3):191-7. Epub 2007 Jun 20.

PMID:
17564773
14.

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.

Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA.

Ann Rheum Dis. 2007 Sep;66(9):1259-62. Epub 2007 Apr 5.

15.

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.

Vallerskog T, Heimbürger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmström V.

Arthritis Res Ther. 2006;8(6):R167.

16.

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.

Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X.

Ann Rheum Dis. 2007 May;66(5):700-3. Epub 2006 Oct 13.

17.

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.

Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O.

Arthritis Res Ther. 2006;8(4):R129.

18.

Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells.

Lee CV, Hymowitz SG, Wallweber HJ, Gordon NC, Billeci KL, Tsai SP, Compaan DM, Yin J, Gong Q, Kelley RF, DeForge LE, Martin F, Starovasnik MA, Fuh G.

Blood. 2006 Nov 1;108(9):3103-11. Epub 2006 Jul 13.

19.

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM; DANCER Study Group.

Arthritis Rheum. 2006 May;54(5):1390-400.

20.

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.

Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR.

Arthritis Res Ther. 2006;8(3):R74. Epub 2006 Apr 21. Erratum in: Arthritis Res Ther. 2008;10(5):406.

Supplemental Content

Support Center